Clinical Trials Logo

Clinical Trial Summary

All participants who completed the prior study to assess long-term safety, tolerability, pharmacokinetics and efficacy, and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll in this open-label extension (OLE) study for up to an additional 24 months of treatment. Approximately 63 participants will be offered to continue at the previously received dose of Recifercept either Low Dose Medium Dose High Dose or at the therapeutic dose once it is identified. Participants will attend the clinic monthly for 24 months. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements & patient/caregiver quality of life questionnaires.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05116046
Study type Interventional
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 7, 2021
Completion date January 3, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04554940 - A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia Phase 2
Completed NCT01435629 - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin N/A
Active, not recruiting NCT03583697 - A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia Phase 2
Completed NCT01516229 - Special Survey for Long Term Application N/A
Completed NCT03872531 - Lifetime Impact Study for Achondroplasia
Recruiting NCT04265651 - Study of Infigratinib in Children With Achondroplasia Phase 2
Active, not recruiting NCT03780153 - The Norwegian Adult Achondroplasia Study
Enrolling by invitation NCT04085523 - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia Phase 2
Recruiting NCT03875534 - A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
Recruiting NCT03794609 - Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
Enrolling by invitation NCT03989947 - An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia Phase 2
Active, not recruiting NCT02724228 - A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) Phase 2
Completed NCT02055157 - A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia Phase 2
Completed NCT01590446 - A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers Phase 1
Completed NCT01541306 - C-Type Natriuretic Peptide and Achondroplasia N/A
Recruiting NCT04184817 - Radiological Analysis on Patients With Achondroplasia Disorder
Recruiting NCT04638153 - A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia Phase 2
Completed NCT03449368 - Lifetime Impact of Achondroplasia Study in Europe-LIAISE
Active, not recruiting NCT03424018 - An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Phase 3
Completed NCT03197766 - A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Phase 3